Annual CFF
-$24.09 M
-$21.23 M-742.50%
31 December 2023
Summary:
Arcturus Therapeutics Holdings annual cash flow from financing activities is currently -$24.09 million, with the most recent change of -$21.23 million (-742.50%) on 31 December 2023. During the last 3 years, it has fallen by -$460.23 million (-105.52%). ARCT annual CFF is now -105.52% below its all-time high of $436.14 million, reached on 31 December 2020.ARCT Cash From Financing Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Quarterly CFF
$693.00 K
-$1.71 M-71.16%
30 September 2024
Summary:
Arcturus Therapeutics Holdings quarterly cash flow from financing activities is currently $693.00 thousand, with the most recent change of -$1.71 million (-71.16%) on 30 September 2024. Over the past year, it has dropped by -$21.15 million (-96.83%). ARCT quarterly CFF is now -99.63% below its all-time high of $187.22 million, reached on 30 September 2020.ARCT Quarterly CFF Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
TTM CFF
-$13.37 M
-$21.15 M-272.02%
30 September 2024
Summary:
Arcturus Therapeutics Holdings TTM cash flow from financing activities is currently -$13.37 million, with the most recent change of -$21.15 million (-272.02%) on 30 September 2024. Over the past year, it has dropped by -$5.71 million (-74.54%). ARCT TTM CFF is now -102.77% below its all-time high of $483.04 million, reached on 31 March 2021.ARCT TTM CFF Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
ARCT Cash From Financing Performance
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly | TTMTTM |
|---|---|---|---|
| 1 y1 year | -742.5% | -96.8% | -74.5% |
| 3 y3 years | -105.5% | +0.1% | -106.3% |
| 5 y5 years | -336.1% | -96.8% | -128.6% |
ARCT Cash From Financing High & Low
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | TTM vs highTTM vs high | TTM vs lowTTM vs low | |
|---|---|---|---|---|---|---|---|
| 3 y | 3 years | -105.5% | at low | -96.8% | +102.5% | -106.3% | +56.5% |
| 5 y | 5 years | -105.5% | at low | -99.6% | +102.5% | -102.8% | +56.5% |
| alltime | all time | -105.5% | at low | -99.6% | +102.5% | -102.8% | +56.5% |
Arcturus Therapeutics Holdings Cash From Financing History
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Sept 2024 | - | $693.00 K(-71.2%) | -$13.37 M(-272.0%) |
| June 2024 | - | $2.40 M(+9.8%) | $7.77 M(+42.3%) |
| Mar 2024 | - | $2.19 M(-111.7%) | $5.46 M(-122.7%) |
| Dec 2023 | -$24.09 M(+742.5%) | -$18.66 M(-185.4%) | -$24.09 M(+214.4%) |
| Sept 2023 | - | $21.84 M(>+9900.0%) | -$7.66 M(-75.1%) |
| June 2023 | - | $94.00 K(-100.3%) | -$30.72 M(+0.5%) |
| Mar 2023 | - | -$27.36 M(+1126.0%) | -$30.56 M(+968.9%) |
| Dec 2022 | -$2.86 M(-106.0%) | -$2.23 M(+83.0%) | -$2.86 M(+620.2%) |
| Sept 2022 | - | -$1.22 M(-574.7%) | -$397.00 K(-126.2%) |
| June 2022 | - | $257.00 K(-23.5%) | $1.51 M(+13.1%) |
| Mar 2022 | - | $336.00 K(+46.1%) | $1.34 M(-97.2%) |
| Dec 2021 | $48.02 M(-89.0%) | $230.00 K(-66.8%) | $48.02 M(-77.2%) |
| Sept 2021 | - | $692.00 K(+743.9%) | $210.99 M(-46.9%) |
| June 2021 | - | $82.00 K(-99.8%) | $397.52 M(-17.7%) |
| Mar 2021 | - | $47.01 M(-71.2%) | $483.04 M(+10.8%) |
| Dec 2020 | $436.14 M(+940.7%) | $163.20 M(-12.8%) | $436.14 M(+56.9%) |
| Sept 2020 | - | $187.22 M(+118.7%) | $277.98 M(+148.0%) |
| June 2020 | - | $85.60 M(>+9900.0%) | $112.08 M(+166.7%) |
| Mar 2020 | - | $118.00 K(-97.7%) | $42.02 M(+0.3%) |
| Dec 2019 | $41.91 M(+310.7%) | $5.03 M(-76.4%) | $41.91 M(-10.3%) |
| Sept 2019 | - | $21.33 M(+37.2%) | $46.74 M(+84.0%) |
| June 2019 | - | $15.55 M(>+9900.0%) | $25.40 M(+156.3%) |
| Mar 2019 | - | $0.00(-100.0%) | $9.91 M(-2.9%) |
| Dec 2018 | $10.20 M | $9.87 M(<-9900.0%) | $10.20 M(+635.2%) |
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Sept 2018 | - | -$19.00 K(-133.3%) | $1.39 M(-25.4%) |
| June 2018 | - | $57.00 K(-80.6%) | $1.86 M(-74.5%) |
| Mar 2018 | - | $294.00 K(-72.2%) | $7.29 M(+4.2%) |
| Dec 2017 | $7.00 M(+267.9%) | $1.06 M(+133.1%) | $7.00 M(+17.9%) |
| Sept 2017 | - | $453.00 K(-91.7%) | $5.94 M(+8.3%) |
| June 2017 | - | $5.49 M(>+9900.0%) | $5.48 M(<-9900.0%) |
| Mar 2017 | - | $0.00(-100.0%) | -$6000.00(<-9900.0%) |
| Dec 2016 | - | -$6000.00(<-9900.0%) | $0.00(-100.0%) |
| Sept 2016 | - | $0.00(0.0%) | -$26.01 M(0.0%) |
| June 2016 | - | $0.00(-100.0%) | -$26.01 M(+0.1%) |
| Mar 2016 | - | $6000.00(-100.0%) | -$26.00 M(-1466.7%) |
| Dec 2015 | $1.90 M(>+9900.0%) | -$26.01 M(<-9900.0%) | $1.90 M(-93.2%) |
| Sept 2015 | - | $0.00(-100.0%) | $27.92 M(0.0%) |
| June 2015 | - | $13.00 K(-100.0%) | $27.92 M(+0.0%) |
| Mar 2015 | - | $27.90 M(>+9900.0%) | $27.90 M(>+9900.0%) |
| Dec 2014 | $0.00(-100.0%) | $0.00(0.0%) | $0.00(-100.0%) |
| Sept 2014 | - | $0.00(0.0%) | $35.36 M(0.0%) |
| June 2014 | - | $0.00(0.0%) | $35.36 M(-38.3%) |
| Mar 2014 | - | $0.00(-100.0%) | $57.28 M(-0.2%) |
| Dec 2013 | $57.40 M(+9450.4%) | $35.36 M(>+9900.0%) | $57.40 M(+160.5%) |
| Sept 2013 | - | $0.00(-100.0%) | $22.04 M(0.0%) |
| June 2013 | - | $21.92 M(>+9900.0%) | $22.04 M(>+9900.0%) |
| Mar 2013 | - | $115.00 K | $115.00 K |
| Dec 2012 | $601.00 K(-77.1%) | - | - |
| Dec 2011 | $2.62 M | - | - |
FAQ
- What is Arcturus Therapeutics Holdings annual cash flow from financing activities?
- What is the all time high annual CFF for Arcturus Therapeutics Holdings?
- What is Arcturus Therapeutics Holdings annual CFF year-on-year change?
- What is Arcturus Therapeutics Holdings quarterly cash flow from financing activities?
- What is the all time high quarterly CFF for Arcturus Therapeutics Holdings?
- What is Arcturus Therapeutics Holdings quarterly CFF year-on-year change?
- What is Arcturus Therapeutics Holdings TTM cash flow from financing activities?
- What is the all time high TTM CFF for Arcturus Therapeutics Holdings?
- What is Arcturus Therapeutics Holdings TTM CFF year-on-year change?
What is Arcturus Therapeutics Holdings annual cash flow from financing activities?
The current annual CFF of ARCT is -$24.09 M
What is the all time high annual CFF for Arcturus Therapeutics Holdings?
Arcturus Therapeutics Holdings all-time high annual cash flow from financing activities is $436.14 M
What is Arcturus Therapeutics Holdings annual CFF year-on-year change?
Over the past year, ARCT annual cash flow from financing activities has changed by -$21.23 M (-742.50%)
What is Arcturus Therapeutics Holdings quarterly cash flow from financing activities?
The current quarterly CFF of ARCT is $693.00 K
What is the all time high quarterly CFF for Arcturus Therapeutics Holdings?
Arcturus Therapeutics Holdings all-time high quarterly cash flow from financing activities is $187.22 M
What is Arcturus Therapeutics Holdings quarterly CFF year-on-year change?
Over the past year, ARCT quarterly cash flow from financing activities has changed by -$21.15 M (-96.83%)
What is Arcturus Therapeutics Holdings TTM cash flow from financing activities?
The current TTM CFF of ARCT is -$13.37 M
What is the all time high TTM CFF for Arcturus Therapeutics Holdings?
Arcturus Therapeutics Holdings all-time high TTM cash flow from financing activities is $483.04 M
What is Arcturus Therapeutics Holdings TTM CFF year-on-year change?
Over the past year, ARCT TTM cash flow from financing activities has changed by -$5.71 M (-74.54%)